Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct information

Dosage forms and strengths

2 evidence topics · 2 sources

IMPALA-2 investigational formulation
AttributeReported value
Dosage form“Nebulizer solution”
Concentration“250 µg/mL”
Material safety data sheet

No evidence found.